Lv4
750 积分 2022-04-27 加入
Recent Developments in the Management of Renal Cell Cancer
5天前
已关闭
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
2个月前
已完结
Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports
3个月前
已完结
Molecular Insights Into the Origin, Biology, and Treatment of Anaplastic Thyroid Carcinoma
3个月前
已关闭
The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors
3个月前
已完结
The Role of Molecular Markers in Thyroid Cancer Diagnostics and Treatment
3个月前
已完结
Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis
4个月前
已完结
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions
4个月前
已完结
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
4个月前
已完结
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
4个月前
已完结
皖公网安备34019202002308
